

10/578953

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AP20 REC'D ON 10 MAY 2006

Applicants: Philippe G. Nantermet et al.
Serial No.: To Be Assigned Case No.: 21585YP
US Nat'l Filing Date: May 10, 2006
Int'l Appl'n No. PCT/US2004/038927
Int'l Filing Date: 19 November 2004
For: BENZYLETHER AND BENZYLAMINO BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

MAIL STOP PCT
Commissioner for Patents
P.O. BOX 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97**

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT May 10, 2006
EXPRESS MAIL NO. EL 189585288US

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail "Post Office to Addressee" on the above date in an envelope addressed to:

Commissioner for Patents, P. O. Box 1450,
Alexandria, Virginia 22313-1450

MAILED BY Christine Coffey
DATE 5-10-06

10/578953

Int'l Appl'n No.: PCT/US2004/038927
Case No.: 21585YP
Page 2


This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Reference A on the accompanying PTO 1440 form was cited in the International Search Report for this application. A copy of the International Search Report is enclosed with this Information Disclosure Statement.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application. Accordingly, it is believed that no fee is due. Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By 
John C. Todaro, Reg. No. 36,036
Attorney for Applicant

MERCK & CO., Inc.
P.O. Box 2000
Rahway, New Jersey 07065-0907
(732) 594-0125

Date: May 10, 2006

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

<p>Substitute for form 1449A/PTO</p> <p>INFORMATION DISCLOSURE</p> <p>STATEMENT BY APPLICANT</p> <p><i>(use as many sheets as necessary)</i></p>				<p>COMPLETE IF KNOWN</p>	
				Application Number	To Be Assigned
				Filing Date	May 10, 2006
				First Named Inventor	Philippe C. Nantermet
				Group Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	2	Attorney Docket Number	21585YP

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
B	PCT	WO 2004/043916			Merck & Co., Inc.	05/27/2004
C	PCT	WO 2005/004802			Merck & Co., Inc.	01/20/2005
D	PCT	WO 2005/004803			Merck & Co., Inc.	01/20/2005
E	PCT	WO 2005/032471			Merck & Co., Inc.	04/14/2005
F	PCT	WO 2003/106405			Sunesis Pharmaceuticals, Inc.	12/24/2003
G	PCT	WO 2005/005374			Sunesis Pharmaceuticals, Inc.	01/20/2005

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., -7/12/2005

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2 Attorney Docket Number 21585YP

NON PATENT LITERATURE DOCUMENTS

Examiner Signature _____ Date Considered _____

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Computer generated form "IDS Form" (IDS Folder) Merck & Co., Inc. -7/12/2005